Skip to content

The Cytoadherence in Pediatric Malaria (CPM) Study

Clinical Outcomes in Pediatric Plasmodium Falciparum Malaria According to Host Cytoadherence Factors

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00707200
Acronym
CPM
Enrollment
2000
Registered
2008-06-30
Start date
2007-10-31
Completion date
2009-11-30
Last updated
2010-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plasmodium Falciparum Malaria

Keywords

severe malarial anemia (SMA), cerebral malarial (CM), lactic acidosis, hyperparasitemia, respiratory distress, hypoxia, death, transfusion

Brief summary

The purpose of this study is to determine the importance of key blood group molecules in the clinical outcome of Plasmodium falciparum malaria infection in children.

Detailed description

Every year, nearly 2 million children die from infection with Plasmodium falciparum malaria. When red blood cells (RBC) become infected with malaria, a sticky parasite-derived knob protein, termed PfEMP-1, erupts on the RBC surfaces. PfEMP-1 attaches to several blood group molecules, including those found on other RBC, on blood vessels, and on the cells that normally help to stop bleeding (platelets). The cellular sticking results in a dangerous interruption in blood flow to vital organs, causing brain injury (cerebral malaria), systemic shock (lactic acidosis), and death. Depending on an individual's inherited blood groups of relevance, adhesion may be extensive or limited. In the laboratory, PfEMP-1 adheres to RBCs via the A or B (but not the O) antigens of the ABO blood group system, and to platelets and blood vessels via platelet glycoprotein IV (CD36) and ICAM-1. Consistent with the expected evolutionary advantage of being deficient in these binding targets, blood type O and low-expression of CD36 are found more frequently among Africans. The Cytoadherence in Pediatric Malaria (CPM) project is determining the distribution of adhesive blood group molecules in a cohort of 2000 Ugandan children according to the extent of malaria severity and death, and thus their ultimate clinical and evolutionary significance in malarial survival. This knowledge may serve as the grounds for developing targeted cytoadhesion-interruption therapies in our fight against malaria.

Interventions

None listed

Sponsors

University of Toronto
CollaboratorOTHER
University Health Network, Toronto
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Months to 12 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of Plasmodium falciparum malaria infection

Exclusion criteria

* HIV or significant malnutrition

Design outcomes

Primary

MeasureTime frame
Combined severe morbidity & mortalityDischarge

Secondary

MeasureTime frame
Laboratory indices of potential cytoadhesion (lactate, cell counts)Presentation

Countries

Uganda

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026